Sipavibart
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | SARS-CoV-2 |
| Clinical data | |
| Other names | AZD-3152 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Sipavibart is an experimental medication under investigation for the prevention of COVID‑19 in people who are immunocompromised.[1] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.[1][2]
Society and culture
[edit]Legal status
[edit]In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID‑19 in immunocompromised people aged twelve years of age and older.[1] Kavigale was reviewed under the EMA's accelerated assessment program.[1] The applicant for this medicinal product is AstraZeneca AB.[1]
Names
[edit]Sipavibart is the international nonproprietary name.[3]
References
[edit]- ^ a b c d e "Kavigale EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 15 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Sipavibart (Code C200075)". NCI Thesaurus. 25 November 2024. Retrieved 16 December 2024.
- ^ World Health Organization (2024). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information. 38 (1). hdl:10665/378096.
Further reading
[edit]- Loubet P, Gaborit B, Salpin M, Gardeney H, Benotmane I, Systchenko T (December 2024). "Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France". Human Vaccines & Immunotherapeutics. 20 (1): 2387221. doi:10.1080/21645515.2024.2387221. PMC 11328879. PMID 39143811.
- Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, et al. (2024). "Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies". Pathogens & Immunity. 10 (1): 1–11. doi:10.20411/pai.v10i1.752. PMC 11464000. PMID 39391808.
.svg){kind=small}
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |